Poly-DL-lactide-co-glycolide microspheres as a controlled release antigen delivery system
Autor(a) principal: | |
---|---|
Data de Publicação: | 1999 |
Outros Autores: | |
Tipo de documento: | Artigo |
Idioma: | eng |
Título da fonte: | Brazilian Journal of Medical and Biological Research |
Texto Completo: | http://old.scielo.br/scielo.php?script=sci_arttext&pid=S0100-879X1999000200005 |
Resumo: | Successful vaccine application means maximum protection with minimal number of administrations. A rational development of vaccines involves studies of the nature of the antigen as well as of the adjuvant to be used to improve the immune responses. This has provided the impetus for studies to design the degradable devices and for different approaches to antigen delivery by different routes of administration. The development of controlled release systems based on polymeric devices that permit a sustained or pulsed release of encapsulated antigens has attracted much interest. Polymeric delivery systems consist of polymers that release their content continuously in a controlled manner over a period of time. The development of a biocompatible delivery system for parenteral administration offers several advantages in terms of immunoadjuvanticity over other compounds. It was found that, in contrast to other carriers, microspheres are more stable, thus permitting administration by the oral or parenteral route. In the present study, we describe the main characteristics and potentialities of this new immunoadjuvant for oral and parenteral administration. |
id |
ABDC-1_236e317dba04f01cfef26d81869b256d |
---|---|
oai_identifier_str |
oai:scielo:S0100-879X1999000200005 |
network_acronym_str |
ABDC-1 |
network_name_str |
Brazilian Journal of Medical and Biological Research |
repository_id_str |
|
spelling |
Poly-DL-lactide-co-glycolide microspheres as a controlled release antigen delivery systemvaccineadjuvantmicrospheresmicroencapsulationbiomaterialSuccessful vaccine application means maximum protection with minimal number of administrations. A rational development of vaccines involves studies of the nature of the antigen as well as of the adjuvant to be used to improve the immune responses. This has provided the impetus for studies to design the degradable devices and for different approaches to antigen delivery by different routes of administration. The development of controlled release systems based on polymeric devices that permit a sustained or pulsed release of encapsulated antigens has attracted much interest. Polymeric delivery systems consist of polymers that release their content continuously in a controlled manner over a period of time. The development of a biocompatible delivery system for parenteral administration offers several advantages in terms of immunoadjuvanticity over other compounds. It was found that, in contrast to other carriers, microspheres are more stable, thus permitting administration by the oral or parenteral route. In the present study, we describe the main characteristics and potentialities of this new immunoadjuvant for oral and parenteral administration.Associação Brasileira de Divulgação Científica1999-02-01info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersiontext/htmlhttp://old.scielo.br/scielo.php?script=sci_arttext&pid=S0100-879X1999000200005Brazilian Journal of Medical and Biological Research v.32 n.2 1999reponame:Brazilian Journal of Medical and Biological Researchinstname:Associação Brasileira de Divulgação Científica (ABDC)instacron:ABDC10.1590/S0100-879X1999000200005info:eu-repo/semantics/openAccessLima,K.M.Rodrigues Júnior,J.M.eng1999-02-04T00:00:00Zoai:scielo:S0100-879X1999000200005Revistahttps://www.bjournal.org/https://old.scielo.br/oai/scielo-oai.phpbjournal@terra.com.br||bjournal@terra.com.br1414-431X0100-879Xopendoar:1999-02-04T00:00Brazilian Journal of Medical and Biological Research - Associação Brasileira de Divulgação Científica (ABDC)false |
dc.title.none.fl_str_mv |
Poly-DL-lactide-co-glycolide microspheres as a controlled release antigen delivery system |
title |
Poly-DL-lactide-co-glycolide microspheres as a controlled release antigen delivery system |
spellingShingle |
Poly-DL-lactide-co-glycolide microspheres as a controlled release antigen delivery system Lima,K.M. vaccine adjuvant microspheres microencapsulation biomaterial |
title_short |
Poly-DL-lactide-co-glycolide microspheres as a controlled release antigen delivery system |
title_full |
Poly-DL-lactide-co-glycolide microspheres as a controlled release antigen delivery system |
title_fullStr |
Poly-DL-lactide-co-glycolide microspheres as a controlled release antigen delivery system |
title_full_unstemmed |
Poly-DL-lactide-co-glycolide microspheres as a controlled release antigen delivery system |
title_sort |
Poly-DL-lactide-co-glycolide microspheres as a controlled release antigen delivery system |
author |
Lima,K.M. |
author_facet |
Lima,K.M. Rodrigues Júnior,J.M. |
author_role |
author |
author2 |
Rodrigues Júnior,J.M. |
author2_role |
author |
dc.contributor.author.fl_str_mv |
Lima,K.M. Rodrigues Júnior,J.M. |
dc.subject.por.fl_str_mv |
vaccine adjuvant microspheres microencapsulation biomaterial |
topic |
vaccine adjuvant microspheres microencapsulation biomaterial |
description |
Successful vaccine application means maximum protection with minimal number of administrations. A rational development of vaccines involves studies of the nature of the antigen as well as of the adjuvant to be used to improve the immune responses. This has provided the impetus for studies to design the degradable devices and for different approaches to antigen delivery by different routes of administration. The development of controlled release systems based on polymeric devices that permit a sustained or pulsed release of encapsulated antigens has attracted much interest. Polymeric delivery systems consist of polymers that release their content continuously in a controlled manner over a period of time. The development of a biocompatible delivery system for parenteral administration offers several advantages in terms of immunoadjuvanticity over other compounds. It was found that, in contrast to other carriers, microspheres are more stable, thus permitting administration by the oral or parenteral route. In the present study, we describe the main characteristics and potentialities of this new immunoadjuvant for oral and parenteral administration. |
publishDate |
1999 |
dc.date.none.fl_str_mv |
1999-02-01 |
dc.type.driver.fl_str_mv |
info:eu-repo/semantics/article |
dc.type.status.fl_str_mv |
info:eu-repo/semantics/publishedVersion |
format |
article |
status_str |
publishedVersion |
dc.identifier.uri.fl_str_mv |
http://old.scielo.br/scielo.php?script=sci_arttext&pid=S0100-879X1999000200005 |
url |
http://old.scielo.br/scielo.php?script=sci_arttext&pid=S0100-879X1999000200005 |
dc.language.iso.fl_str_mv |
eng |
language |
eng |
dc.relation.none.fl_str_mv |
10.1590/S0100-879X1999000200005 |
dc.rights.driver.fl_str_mv |
info:eu-repo/semantics/openAccess |
eu_rights_str_mv |
openAccess |
dc.format.none.fl_str_mv |
text/html |
dc.publisher.none.fl_str_mv |
Associação Brasileira de Divulgação Científica |
publisher.none.fl_str_mv |
Associação Brasileira de Divulgação Científica |
dc.source.none.fl_str_mv |
Brazilian Journal of Medical and Biological Research v.32 n.2 1999 reponame:Brazilian Journal of Medical and Biological Research instname:Associação Brasileira de Divulgação Científica (ABDC) instacron:ABDC |
instname_str |
Associação Brasileira de Divulgação Científica (ABDC) |
instacron_str |
ABDC |
institution |
ABDC |
reponame_str |
Brazilian Journal of Medical and Biological Research |
collection |
Brazilian Journal of Medical and Biological Research |
repository.name.fl_str_mv |
Brazilian Journal of Medical and Biological Research - Associação Brasileira de Divulgação Científica (ABDC) |
repository.mail.fl_str_mv |
bjournal@terra.com.br||bjournal@terra.com.br |
_version_ |
1754302929660018688 |